Vor Biopharma Inc
VOR0.151USD
-0.008-5.44%
Handelsschluss 05/09, 16:00（ET）Kurse um 15 Minuten verzögert
18.88MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Vor Biopharma Inc Unternehmen
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidates include tremtelectogene empogeditemcel (trem-cel), for the treatment of acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II multicenter, open-label, first-in-human study of trem-cel in patients with AML. Its other clinical trial and pipeline products are VCAR33 / VBP301, Trem-cel+VCAR33 Treatment, System CD33-CLL1 Treatment System, and VADC45.
Unternehmensinformationen
Unternehmens-codeVOR
Name des UnternehmensVor Biopharma Inc
IPO-datumFeb 05, 2021
Gegründet am2015
CEODr. Robert Ang, M.D.
Anzahl der mitarbeiter159
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 05
Addresse100 Cambridgepark Drive
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02140
Telefon16176556580
Websitehttps://www.vorbio.com/
Unternehmens-codeVOR
IPO-datumFeb 05, 2021
Gegründet am2015
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Tirtha Chakraborty, Ph.D.
Dr. Tirtha Chakraborty, Ph.D.
Chief Scientific Officer and Head of Technical Operations
Chief Scientific Officer and Head of Technical Operations
80.28K
-3.40%
Mr. Matthew R. Patterson
Mr. Matthew R. Patterson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
41.20K
+3.36%
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
Independent Director
Independent Director
29.43K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Dr. Han Choi, M.D.
Dr. Han Choi, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Robert Ang, M.D.
Dr. Robert Ang, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Tirtha Chakraborty, Ph.D.
Dr. Tirtha Chakraborty, Ph.D.
Chief Scientific Officer and Head of Technical Operations
Chief Scientific Officer and Head of Technical Operations
80.28K
-3.40%
Mr. Matthew R. Patterson
Mr. Matthew R. Patterson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
41.20K
+3.36%
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
Independent Director
Independent Director
29.43K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Fri, Apr 18
Update-Zeit: Fri, Apr 18
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
RA Capital Management, LP
31.75%
Reprogrammed Interchange LLC
31.22%
5AM Ventures
5.10%
Fidelity Management & Research Company LLC
5.07%
The Vanguard Group, Inc.
1.56%
Other
25.31%
Aktionärsstatistik
Aktionäre
Anteil
RA Capital Management, LP
31.75%
Reprogrammed Interchange LLC
31.22%
5AM Ventures
5.10%
Fidelity Management & Research Company LLC
5.07%
The Vanguard Group, Inc.
1.56%
Other
25.31%
Art
Aktionäre
Anteil
Hedge Fund
33.29%
Corporation
31.22%
Investment Advisor
7.09%
Venture Capital
6.26%
Investment Advisor/Hedge Fund
2.57%
Individual Investor
0.70%
Research Firm
0.21%
Bank and Trust
0.01%
Other
18.65%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
171
101.61M
81.40%
+39.01M
2024Q4
172
101.57M
81.78%
+39.14M
2024Q3
175
49.60M
72.03%
-12.93M
2024Q2
174
56.25M
82.04%
-8.25M
2024Q1
168
60.63M
88.57%
-4.75M
2023Q4
163
60.90M
89.54%
-3.77M
2023Q3
164
61.10M
90.20%
-4.10M
2023Q2
166
61.68M
92.10%
-1.24M
2023Q1
168
61.85M
93.27%
-1.28M
2022Q4
162
61.21M
94.78%
+26.97M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
39.65M
31.75%
+16.90M
+74.28%
Dec 31, 2024
Reprogrammed Interchange LLC
38.97M
31.22%
+38.97M
--
Dec 30, 2024
5AM Ventures
6.36M
5.1%
--
--
Dec 31, 2024
Fidelity Management & Research Company LLC
6.33M
5.07%
-649.38K
-9.30%
Dec 31, 2024
The Vanguard Group, Inc.
1.94M
1.56%
-11.46K
-0.59%
Dec 31, 2024
Johnson & Johnson Innovation-JJDC, Inc.
1.07M
0.86%
--
--
Dec 31, 2024
Lynx1 Capital Advisors LLC
637.22K
0.51%
+637.22K
--
Dec 31, 2024
Sarissa Capital Management, L.P.
618.00K
0.49%
--
--
Dec 31, 2024
Ang (Robert M.D.)
646.69K
0.52%
+131.47K
+25.52%
Feb 06, 2025
Renaissance Technologies LLC
529.50K
0.42%
-226.51K
-29.96%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Tue, May 6
Update-Zeit: Tue, May 6
Name
Anteil
Range Cancer Immunotherapy ETF
1.25%
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
Mehr Anzeigen
Range Cancer Immunotherapy ETF
Anteil1.25%
iShares Micro-Cap ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
Global X Russell 2000 Covered Call ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten